Jefferies Sticks to Its Buy Rating for Boston Scientific (BSX)
Jefferies and Citi maintained Buy ratings on Boston Scientific (BSX) with price targets of $60 and $57, respectively. The company reported Q2 revenue of $5.44B and net profit of $907M, up from last year's $5.06B and $793M. Insider activity is positive, with recent purchases by directors.
How this was made
The 30-second read
Why it matters
Earnings beat and maintained Buy rating could reinforce bullish sentiment, but lack of rating change may cap upside.
Market read
Positive earnings and analyst endorsement provide a modest trade catalyst for BSX.
What to watch
Potential headwinds from supply chain constraints or regulatory reviews are not discussed.
Background
Boston Scientific's quarterly earnings release and analyst coverage update.
Ticker impact
Boston Scientific reported Q2 revenue of $5.44B and net profit of $907M, and Jefferies maintained a Buy rating with a $60 price target.
Potential modest price appreciation in the next few days.
Revenue and profit growth year‑over‑year, combined with a maintained Buy rating, suggest continued investor confidence.
Market effects
Healthcare equipment sector may see modest uplift as a large medtech player reports solid growth.
U.S. markets could see a slight positive bias in medtech stocks.
Limited to U.S. and global medtech investors.
Counterpoint
The rating is unchanged; some investors may view the lack of upgrade as a sign of limited upside.
Key entities
- CompanyBoston Scientific
Medical device manufacturer (ticker BSX).
- Analyst FirmJefferies
Maintained Buy rating with $60 price target.
